Skip to main content

REVIEW article

Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1517604
This article is part of the Research Topic RNA Modifications in Cancer: Unraveling Roles and Therapeutic Potential in Immunity and Immunotherapy View all 5 articles

Harnessing m1A Modification: A New Frontier in Cancer Immunotherapy

Provisionally accepted
Lin Yang Lin Yang 1,2*Xinru Wang Xinru Wang 1Xiaoqing Ma Xiaoqing Ma 1Siyu Chen Siyu Chen 1Minyan Fan Minyan Fan 1Chenying Jin Chenying Jin 1Yushi Chen Yushi Chen 1Shaodong Wang Shaodong Wang 3Zhiying Wang Zhiying Wang 4Fei Meng Fei Meng 5Chengwan Zhang Chengwan Zhang 6
  • 1 China Pharmaceutical University, Nanjing, China
  • 2 Jiangsu Key Laboratory of Carcinogenesis and Intervention, China Pharmaceutical University, Nanjing, Jiangsu Province, China
  • 3 Affiliated Jinling Hospital, School of Medicine, Nanjing University, Nanjing, Jiangsu Province, China
  • 4 Department of Gastroenterology, Qingdao Municipal Hospital, Qingdao, China
  • 5 Department of Clinical Laboratory, Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nangjing, China
  • 6 Department of Central Laboratory, The Affiliated Huaian No. 1 People’s Hospital of Nanjing Medical University, Huaian, China

The final, formatted version of the article will be published soon.

    modification is an epigenetic change that occurs on RNA molecules, regulated by a suite of enzymes including methyltransferases (writers), demethylases (erasers), and m1A-recognizing proteins (readers). This modification significantly impacts the function of RNA and various biological processes by affecting the structure, stability, translation, metabolism, and gene expression of RNA. Thereby, m1A modification is closely associated with the occurrence and progression of cancer. This review aims to explore the role of m1A modification in tumor immunity. m1A affects tumor immune responses by directly regulating immune cells and indirectly modulating tumor microenvironment. Besides, we also discuss the implications of m1A-mediated metabolic reprogramming and its nexus with immune checkpoint inhibitors, unveiling promising avenues for immunotherapeutic intervention. Additionally, the m1AScore, established based on the expression patterns of m1A modification, can be used to predict tumor prognosis and guide personalized therapy. Our review underscores the significance of m1A modification as a burgeoning frontier in cancer biology and immuno-oncology, with the potential to revolutionize cancer treatment strategies.

    Keywords: m1A modification, cancer immunotherapy, Tumor Microenvironment, m1AScore, Immune check inhibitor

    Received: 26 Oct 2024; Accepted: 18 Nov 2024.

    Copyright: © 2024 Yang, Wang, Ma, Chen, Fan, Jin, Chen, Wang, Wang, Meng and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Lin Yang, China Pharmaceutical University, Nanjing, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.